Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 51 (1), 271-8

Advancements in Cancer Therapy With Alpha-Emitters: A Review


Advancements in Cancer Therapy With Alpha-Emitters: A Review

S K Imam. Int J Radiat Oncol Biol Phys.


Purpose: This synopsis attempts to shed light on the progresses made in the field of cancer therapy using alpha-particles.

Hurdles and progresses: The rationale of selection of radionuclides focusing on comparison of alpha- and beta-emitters, the hurdles and their solutions, and recent developments are addressed. The efforts made in the field of alpha-radioimmunotherapy of hematologic malignancies are emphasized. A good deal of progress has been achieved in the past decade, and preclinical studies with a variety of radioimmunoconjugates with astatine and bismuth radioisotopes (At-211, Bi-212, and Bi-213) have generated encouraging results, providing an impetus for future clinical trials.

Conclusion: The onset of early clinical trials with alpha-emitters will hopefully enable the cancer researchers to come up with extremely effective and highly specific "smart bombs" to target cancer cells.

Similar articles

See all similar articles

Cited by 12 articles

See all "Cited by" articles

LinkOut - more resources